Teva president and CEO Kåre Schultz has made clear his “frustration” over legal uncertainties that are hanging over the company, which has registered a related goodwill impairment of $4.628bn as it reported its third-quarter results, plunging it into a multi-billion dollar loss.
Teva’s Legal Woes Lead To $4.6bn Hit
‘Frustrating’ Legal Situation On Price-Fixing Could Last For Years
Teva reported a substantial loss in the third quarter after registering a goodwill impairment of $4.6bn, largely linked to legal uncertainties as the firm continues to grapple with price-fixing litigation in the US and its pending opioids settlement.
